Optimal Scan Time of (18)F-FDG PET in Identifying Therapeutic Efficacy Secondary to Radiofrequency Ablation of Lung Cancer: Case Report

Positron emission tomography (PET)/computed tomography (CT)–guided radiofrequency ablation (RFA) has become a major treatment approach for small tumors. Identifying this quantitative dynamic (18)F-2-fluoro-2-deoxy-d-glucose ((18)F-FDG) activity at the primary lesion can minimize misdiagnosis and all...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Wen-Qian, Fu, Yi-Li, Hu, Bin, Chen, Shuo, Yang, Min-Fu, Li, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2015
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616549/
https://www.ncbi.nlm.nih.gov/pubmed/26091453
http://dx.doi.org/10.1097/MD.0000000000000884
Descripción
Sumario:Positron emission tomography (PET)/computed tomography (CT)–guided radiofrequency ablation (RFA) has become a major treatment approach for small tumors. Identifying this quantitative dynamic (18)F-2-fluoro-2-deoxy-d-glucose ((18)F-FDG) activity at the primary lesion can minimize misdiagnosis and allow an opportunity to reintervene. Here, we report 3 patients with nonsmall cell lung cancer (NSCLC) who underwent the ablative therapy with split-dose (18)F-FDG fused PET/CT scans for early identification of residual tumors and follow-up evaluation of treatment. Our results indicate that reliable post-RFA imaging follow-up is critical in fast and efficient assessment of complete tumor resection in patients experienced the ablation procedure.

Ejemplares similares